drugset / Trial / NCT02678182
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
Phase 2
Active not recruiting
494 enrolled
Royal Marsden NHS Foundation Trust
AstraZeneca · collabClovis Oncology, Inc. · collabEli Lilly and Company · collabMedImmune LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy of maintenance therapies following completion of standard first-line chemotherapy in patients with locally advanced or metastatic HER-2 positive or HER-2 negative oesophago-gastric adenocarcinomas.
Timeline
- Start
- 2015-02
- Primary completion
- 2025-04-17
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Rucaparib | Small molecule | 600 mg | Oral |
| Comparator | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |